Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2022 | The TAUTEM study: transanal endoscopic microsurgery vs. total mesorectal excision

Patient quality of life is often at a detriment when using total mesorectal excision (TME) for the treatment of rectal adenocarcinom. Xavier Serra-Aracil, MD, PhD, Parc Tauli University Hospital, Barcelona, Spain, discusses preoperative, surgical and pathological outcomes from the TAUTEM study (NCT01308190), a prospective, multicenter, randomized controlled non-inferiority trial which aims to demonstrate the non-inferiority of the oncological outcomes and the improvement in morbidity and quality of life achieved with chemoradiotherapy and transanal endoscopic microsurgery (CRT-TEM) compared with TME. CRT-TEM treatment obtains high pathological complete response rates (45.3%), with a high CRT compliance rate (97.6%) and low morbidity. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.